1197199-79-3

Basic information

• Product Name: N-(7-[4-fluorophenyl]quinazolin-4-yl)-4-((1-(phenylthio)ethan-2-yl)amino)-3-nitrobenzenesulfonamide
• CAS NO: 1197199-79-3
• Molecular Weight: 575.644
• Mol File: 1197199-79-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(7-[4-fluorophenyl]quinazolin-4-yl)-4-((1-(phenylthio)ethan-2-yl)amino)-3-nitrobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(7-[4-fluorophenyl]quinazolin-4-yl)-4-((1-(phenylthio)ethan-2-yl)amino)-3-nitrobenzenesulfonamide(1197199-79-3)
• EPA Substance Registry System: N-(7-[4-fluorophenyl]quinazolin-4-yl)-4-((1-(phenylthio)ethan-2-yl)amino)-3-nitrobenzenesulfonamide(1197199-79-3)

Safety Data

• Hazardous Substances Data: 1197199-79-3(Hazardous Substances Data)

Upstream product

• 97-09-6 4-Chloro-3-nitrobenzenesulfonamide 
• 4110-33-2 2,4-dinitrobenzonitrile 
• 1197199-74-8 C₇H₈O₃S*C₈H₁₁NS 
• 1027345-31-8 4-(4-((4'-chloro-(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)-2-nitrobenzonitrile tosylate 
• 1027345-33-0 7-(4-((4'-chloro-(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)quinazolin-4-amine 
• 1027345-23-8 7-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-yl)quinazolin-4(3H)-one 
• 1027345-32-9 2-amino-4-(4-((4'-chloro-(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzonitrile 
• 1027345-29-4 4-(4-(2-bromobenzyl)piperazin-1-yl)-2-nitrobenzonitrile 
• 1027345-15-8 tert-butyl 4-(4-cyano-3-nitrophenyl)piperazine-1-carboxylate 
• 591-50-4 iodobenzene 
• 406233-13-4 3-nitro-4-(2-phenylsulfanylethylamino)-benzenesulfonamide 
• 1027345-24-9 4-chloro-7-(4-((4'-chloro-(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)quinazoline 
• 1765-93-1 4-fluoroboronic acid 
• 38487-86-4 2-amino-4-chlorobenzonitrile 

Relevant articles and documents

Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity

ABT-737 and ABT-263 are potent inhibitors of the BH3 antiapoptotic proteins, Bcl-xL and Bcl-2. This class of putative anticancer agents invariantly contains an acylsulfonamide core. We have designed and synthesized a series of novel quinazoline-based inhibitors of Bcl-2 and Bcl-xL that contain a heterocyclic alternative to the acylsulfonamide. These compounds exhibit submicromolar, mechanism-based activity in human small-cell lung carcinoma cell lines in the presence of 10% human serum. This comprises the first successful demonstration of a quinazoline sulfonamide core serving as an effective benzoylsulfonamide bioisostere. Additionally, these novel quinazolines comprise only the second known class of Bcl-2 family protein inhibitors to induce mechanism-based cell death.